Redeye provides an update following CLS’s Q3 2026 report. Sales came in below our expectations; however, with the SEK23m ClearPoint order still being delivered, we do not put too much weight on the deviation and believe it opens up for a strong Q4 2026. Cost control remained solid, and the gross margin stayed above the 60% target. Overall, we view the report as mixed, with solid cost control and margins but softer-than-expected sales. We lower our sales estimates as well as our cost estimates, the latter to reflect CLS’s cost focus. Together with a higher risk-free rate, this results in a lower Base Case, and our fair value continues to suggest that the share is cheap.
LÄS MER